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Abstract
Background: Data on high-flow nasal oxygen after thoracic surgery are limited and confined to the comparison with
low-flow oxygen. Different from low-flow oxygen, Venturi masks provide higher gas flow at a predetermined fraction
of inspired oxygen (FiO2). We conducted a randomized trial to determine whether preemptive high-flow nasal oxygen
reduces the incidence of postoperative hypoxemia after lung resection, as compared to Venturi mask oxygen therapy.
Methods: In this single-center, randomized trial conducted in a teaching hospital in Italy, consecutive adult patients
undergoing thoracotomic lung resection, who were not on long-term oxygen therapy, were randomly assigned to
receive high-flow nasal or Venturi mask oxygen after extubation continuously for two postoperative days. The primary
outcome was the incidence of postoperative hypoxemia (i.e., ratio of the partial pressure of arterial oxygen to FiO2
(PaO2/FiO2) lower than 300mmHg) within four postoperative days.
Results: Between September 2015 and April 2018, 96 patients were enrolled; 95 patients were analyzed (47 in
high-flow group and 48 in Venturi mask group). In both groups, 38 patients (81% in the high-flow group and
79% in the Venturi mask group) developed postoperative hypoxemia, with an unadjusted odds ratio (OR) for the
high-flow group of 1.11 [95% confidence interval (CI) 0.41–3] (p = 0.84). No inter-group differences were found in
the degree of dyspnea nor in the proportion of patients needing oxygen therapy after treatment discontinuation
(OR 1.34 [95% CI 0.60–3]), experiencing pulmonary complications (OR 1.29 [95% CI 0.51–3.25]) or requiring
ventilatory support (OR 0.67 [95% CI 0.11–4.18]). Post hoc analyses revealed that PaO2/FiO2 during the study was
not different between groups (p = 0.92), but patients receiving high-flow nasal oxygen had lower arterial pressure
of carbon dioxide, with a mean inter-group difference of 2 mmHg [95% CI 0.5–3.4] (p = 0.009), and were
burdened by a lower risk of postoperative hypercapnia (adjusted OR 0.18 [95% CI 0.06–0.54], p = 0.002).
Conclusions: When compared to Venturi mask after thoracotomic lung resection, preemptive high-flow nasal
oxygen did not reduce the incidence of postoperative hypoxemia nor improved other analyzed outcomes.
Further adequately powered investigations in this setting are warranted to establish whether high-flow nasal
oxygen may yield clinical benefit on carbon dioxide clearance.
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Background
Patients undergoing lung resection are jeopardized by rele-
vant postoperative morbidity and mortality [1–3]. Acute
respiratory failure is the most common life-threatening
complication after thoracic surgery. Supplemental oxygen
is often needed to improve arterial oxygenation in the
postoperative period: despite it is effective in treating most
cases of hypoxemia, patients with low ventilation-perfu-
sion ratio may be only partially responsive to an increase
in oxygen concentration. Noninvasive ventilation (NIV)
has been proposed to prevent/treat respiratory failure after
lung resection [4–8], but its routine use in clinical practice
requires personnel expertise and technological resources
that may not be available in all post-anesthesia care units
and surgical wards. In addition, in the early postoperative
period, delivery of positive pressure in the airways and
eventual patient-ventilator asynchronies during assisted
ventilation may pose a risk to the tightness of bronchial
anastomosis by means of uncontrolled swings in the trans-
mural pressure of the airways.
The use of nasal cannula to deliver high flow rates of
heated and humidified gas at a predetermined fraction of
inspired oxygen (FiO2) is an attractive alternative to con-
ventional oxygen therapy and, possibly, to NIV [9]. The
beneficial effects of high-flow nasal cannula (HFNC) in-
clude (a) delivery of high flows, that better match patients’
peak inspiratory flow, finally enabling administration of
set FiO2; (b) provision of a small degree of positive pres-
sure in the airways, that increases end-expiratory lung vol-
ume; (c) washout of nasopharyngeal dead space, which
enhances carbon dioxide (CO2) removal; and (e) good tol-
erance and comfort [10–14]. HFNC, as compared to
low-flow oxygen, prevents respiratory failure after extuba-
tion in the intensive care unit and is as effective as NIV
after cardiothoracic surgery and in patients with difficult
separation from mechanical ventilation [15–19]. Also
when compared to oxygen therapy with Venturi mask,
which itself produces mid-to-high flows of gas at predeter-
mined FiO2 due to an air entrainment mechanism, HFNC
improves oxygenation, comfort, and CO2 clearance, pos-
sibly facilitating weaning from mechanical ventilation in
critically ill patients [20].
No study ever compared HFNC and Venturi mask for
oxygen therapy after thoracic surgery: we hereby report
the results of a randomized trial conducted to determine
whether early treatment with HFNC, as compared to
Venturi mask, can prevent the development of clinically
relevant hypoxemia after thoracotomic lung lobectomy.
Methods
Study design
This single-center, open-label, randomized controlled
study was conducted in the post-anesthesia care unit, sur-
gical intensive care unit, and thoracic surgical ward of a
tertiary university hospital in Italy, between September
2015 and April 2018. The protocol was approved by the
local ethics committee and was registered on Clinical
Trials.gov (NCT02544477) before trial initiation. The
study was conducted in accordance with the declaration
of Helsinki, and written informed consent was obtained
from all enrolled subjects according to committee
recommendations.
Participants
All adult patients scheduled for elective thoracotomic
pulmonary lobar resection for malignant disease were
eligible for study inclusion. Exclusion criteria were re-
fusal of informed consent, pregnancy, body mass index
≥ 35 kg/m2, history of obstructive sleep apnea syndrome,
long-term oxygen therapy due to chronic pulmonary dis-
ease, presence of tracheostomy, and any nasal/facial de-
fect that could impede HFNC or Venturi mask use.
Patients enrolled in the study were randomized to re-
ceive oxygen therapy by a Venturi face mask or a treat-
ment with HFNC continuously over the course of 48 h
after surgery. A computer-generated random allocation
list was used to allocate enrolled patients to study arms.
Patient management during surgery
All enrolled patients received general anesthesia accord-
ing to the following standard protocols: induction with
propofol 2–3 mg/kg, fentanyl 1.5–2.5 mcg/kg, and
rocuronium bromide 0.9 mg/kg; maintenance provided
by sevoflurane titrated to keep bi-spectral index values
between 40 and 60%, continuous infusion remifentanil
0.05–0.4 mcg/kg/min, repeated boluses of rocuronium
bromide 0.02 mg kg−1 to maintain a train of four of 1–3
by neuromuscular monitoring, and 3–5 ml/kg/h of intra-
venous crystalloids and antibiotic prophylaxis; and post-
operative analgesia was obtained by intercostal nerve
block at the end of the procedure and paracetamol at a
standard dose for the first three postoperative days.
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During surgery, all patients were ventilated with a tidal
volume of 6–8 ml/kg of predicted body weight [21] for
two-lung ventilation and of 5 ml/kg for one-lung ventila-
tion; PEEP was set at 5 cmH2O throughout the whole
surgical procedure. Recruitment maneuvers were per-
formed once (i.e., after lobectomy) in all patients.
At the end of surgery, patients were extubated as the
following criteria were met: spontaneous respiratory ac-
tivity with exhaled tidal volume between 5 and 8ml/kg;
respiratory frequency ranging between 12 and 30
breaths/min; absence of residual neuromuscular block-
ade, as assessed by train-of-four monitoring; peripheral
oxygen saturation (SpO2) ≥ 92%; hemodynamic stability
(heart rate < 120/min; systolic blood pressure between
90 and 160 mmHg; no signs of cardiac ischemia, no
hemodynamically significant arrhythmias and absence of
catecholamines); body temperature ≥ 36 °C; adequate
cough reflex; and absence of copious secretions.
After extubation, enrolled patients were transferred to
either the post-anesthesia care unit or the intensive care
unit, according to the decision of the attending
anesthesiologist, who was not aware of the randomization
arm. According to department guidelines, early intensive
care unit admission was reserved to American Society of
Anesthesiologists’ three patients who were deemed at
high-risk of postoperative complications. Patients treated
in the post-anesthesia care unit were transferred to the
surgical ward within 4–8 h after surgery, unless deemed
clinically inappropriate. Patients treated in the intensive
care unit were transferred to the surgical ward on postop-
erative day 1, unless clinically contraindicated.
Study treatments
All patients had to undergo the assigned treatment
within 30 min after extubation.
Patients in the control group received oxygen therapy
via a Venturi mask (OS/60 K, FIAB, Florence, Italy); pure
O2 flow was set depending on the needed FiO2 accord-
ing to manufacturer recommendations. Patients in the
intervention group received HFNC by AIRVO™ (Fisher
& Paykel Healthcare Ltd., Auckland, New Zealand). The
initial flow rate was 50 l/min and was eventually dimin-
ished in case of intolerance. Humidification chamber
temperature was set at 37 °C and eventually diminished
in case of intolerance.
In both groups, SpO2 was monitored continuously and
FiO2 was titrated on an hour basis to maintain SpO2 be-
tween 92% and 98%. The assigned treatment was admin-
istered continuously until day 2 after surgery, 9.00 a.m.,
when patients were assessed for treatment interruption;
study treatments were discontinued and patients were
deemed weaned from oxygen therapy as the following
criteria were met: respiratory rate ≤ 35 breaths/min; no
recruitment of accessory muscles during calm breathing;
hemodynamic stability (heart rate < 120/min; systolic
blood pressure between 90 and 160 mmHg; no signs of
cardiac ischemia, no hemodynamically significant ar-
rhythmias, and absence of catecholamines); and core
body temperature < 38.5 °C. After day 2, in case of fail-
ure to be weaned from oxygen therapy, all enrolled pa-
tients received Venturi Mask oxygen therapy, as long as
deemed appropriate by the attending physician.
In the surgical ward, patients from both groups under-
went a standard physiotherapy protocol: over the initial
24 h, this consisted of upright positioning, sitting on the
edge of the bed or on the chair, non-resistance leg exer-
cises, and lung expansion maneuvers twice a day (i.e.,
deep diaphragmatic breathing, thoracic expansion exer-
cises, and incentive spirometry). As soon as the patient
was weaned from oxygen therapy, a walking program
was also adopted.
Measurements
Baseline blood gas analysis was obtained in the pre-
operative period. Postoperative blood gas analyses and
dyspnea assessment were performed 1, 3, and 24 h after
extubation and then on a daily basis up to day 4. Chest
X-ray was obtained 2 h after surgery and then on a daily
basis up to postoperative day 3.
Self-assessment of dyspnea (i.e., respiratory disco
mfort-shortness of breath) was performed by a visual
analog scale (VAS) ranging from 0 (no dyspnea) to 10
(maximum dyspnea) (in Additional file 1: Figure S1).
Endpoints
The primary endpoint of the study was the overall inci-
dence of patients developing clinically relevant hypox-
emia (i.e., ratio of the partial pressure of arterial oxygen
(PaO2) to FiO2 (PaO2/FiO2) < 300 mmHg) during the
first four postoperative days.
Secondary outcomes were (i) the need for supplemen-
tal oxygen after study treatment discontinuation and
within 7 days from randomization (i.e., a peripheral ar-
terial oxygen saturation (SpO2) < 93% while breathing
on room air); (ii) the occurrence of postoperative severe
acute respiratory failure requiring ventilatory support;
(iii) the degree of dyspnea over the course of the first
four postoperative days; and (iv) the rate of pulmonary
complications within 7 days after surgery.
In non-prespecified post hoc analyses, we also assessed
(i) the overall incidence of patients developing mode
rate-to-severe hypoxemia (PaO2/FiO2 < 200 mmHg) over
the first 96 h after surgery; (ii) the cumulative incidence
of clinically relevant hypercapnia (i.e., PaCO2 > 45
mmHg) over the course of the first four postoperative
days; (iii) PaO2/FiO2 and PaCO2 over the course of the
first four postoperative days; (iv) the length of hospital
stay; and (v) all-cause 30-day mortality.
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Postoperative severe acute respiratory failure requiring
ventilatory support was defined as the presence of at
least two of the followings: respiratory acidosis (arterial
pH ≤ 7.35 with PaCO2 > 45mmHg); SpO2 < 90% or
PaO2 < 60mmHg at an FiO2 ≥ 0.5; respiratory frequency
> 35/min; altered state of consciousness; and clinical
signs of respiratory muscle fatigue [22]. Respiratory fail-
ure was initially treated with NIV, except when endo-
tracheal intubation was required (i.e., cardiac arrest, loss
of consciousness, psychomotor agitation, massive aspir-
ation, persistent inability to remove respiratory secre-
tions, heart rate < 50/min with loss of alertness, and
severe hemodynamic instability without response to
fluids and vasoactive drugs [22]). Patients with worsen-
ing blood gases and/or persistent tachypnea (respiratory
rate > 35 breaths/min) despite NIV received endo-
tracheal intubation.
Postoperative pulmonary complications were defined as
sub-lobar or lobar atelectasis, detected by the chest X-rays
and scored using the radiological atelectasis score equal or
greater than two [23]; nosocomial pneumonia (new-onset
or progressive pulmonary infiltrates with at least two of
the following: purulent respiratory secretions, temperature
> 38 °C or < 36 °C, and white blood cell count > 12,000/
mm3 or < 4000/mm3) [24]. Non-pulmonary complications
included new-onset cardiac arrhythmias, cardiac ischemia,
hemodynamic instability requiring fluid or vasoactive re-
suscitation, hyperlactatemia, and metabolic acidosis.
The post hoc analyses on PaCO2 and hypercapnia de-
velopment were conducted under the light of the most
recent evidence suggesting a relevant effect of HFNC on
CO2 washout in the upper airways [10–12, 25–27]. Re-
sults on these endpoints should be considered merely
exploratory in nature.
Statistical analysis
Data on the rate of patients experiencing postopera-
tive hypoxemia (defined as a PaO2/FiO2 ratio < 300
mmHg within 96 h after surgery) during Venturi mask
oxygen therapy after lung resection were lacking at
the time of study design, but it was known that 50%
of them show a PaO2/FiO2 < 320 mmHg 24 h after
surgery while on low-flow oxygen [28]. Using a con-
servative approach, we hypothesized a 45%-incidence
of postoperative hypoxemia in the Venturi mask
group, and we estimated that 45 patients per group
were needed to detect a 60% relative reduction in the
rate of the primary endpoint in the intervention
group (estimated absolute risk in the intervention
group, 18%), with a type I error set at 5% and statis-
tical power of 80%. Given an attrition rate lower than
5%, mostly due to protocol violations and crossover
between treatments, we planned to enroll 94 patients.
The analysis was conducted on a “modified intention
-to-treat” population that included all patients who
underwent the allocated treatment for at least 6 h.
Distribution normality was assessed with the
Kolmogorov-Smirnov test. Continuous variables with
normal distribution are reported as means (± standard
deviation), whilst those with non-normal distributions
were expressed as medians (interquartile ranges).
Analysis on the primary efficacy criterion and for other
categorical outcomes was performed with the χ2 test, or
Fisher’s exact test, as appropriate: Cochran–Mantel–
Haenszel statistics are reported for all these results. For
other relevant outcomes whose distribution was statisti-
cally different in the two groups at the univariate ana-
lysis, a logistic regression model was conducted: all
variables with p ≤ 0.20 at the univariate analysis were in-
cluded. Kaplan–Meier curves were plotted to assess the
time from enrollment to the primary endpoint or rele-
vant secondary outcomes by means of the log-rank test;
for secondary outcomes, Cox regression analysis was
also conducted to confirm the independent effect of the
treatment on the time from enrollment to occurrence of
the endpoint: all variables with a log-rank p ≤ 0.20 were
included in the model. Two-way analysis of variance
(ANOVA) for repeated measures with Bonferroni cor-
rection was used to determine the differences in PaO2/
FiO2 ratio, PaCO2, and dyspnea in the two groups. Com-
parisons between groups regarding these variables at
each study timepoint were performed with the Student’s
t test or Mann-Whitney test, as appropriate. Mean dif-
ference and 95% confidence interval (95% CI) are re-
ported for most significant results.
Two-tail p values ≤ 0.05 were considered significant.
Statistical analysis was performed with SPSS software
package (SPSS Inc. Released 2009. PASW Statistics for
Windows, Version 18.0. Chicago: SPSS Inc.).
Results
Between September 2015 and April 2018, of the 522 pa-
tients undergoing thoracic surgery for lung cancer, 99
patients were eligible for inclusion in the study and 96
underwent randomization. All enrolled patients were
successfully extubated at the end of surgery and received
the allocated treatment within 30min after extubation.
One patient from the HFNC group was not included
in the “modified intention-to-treat” population because,
due to intolerance to the device, the patient received the
allocated treatment for less than 6 h. Data from 95 pa-
tients (47 in the HFNC group and 48 in the Venturi
mask group) were analyzed (Fig. 1).
Demographics, most relevant clinical characteristics,
main comorbidities, preoperative arterial blood gases
and respiratory function, and surgical procedures are re-
ported in Table 1 and were well balanced in the two
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study groups. No patient had preoperative PaCO2 ex-
ceeding 45 mmHg. All patients had undergone thoraco-
tomic lung lobar resection; mean duration of mechanical
ventilation before extubation was 215 min ± 59 in the
HFNC group and 222 ± 119 in the Venturi mask group.
Mean HFNC FiO2 at treatment start was 41% ± 5, with
gas flow set at 50 l/min in all patients. In the Venturi mask
group, mean FiO2 at treatment initiation was 39% ± 4 with
a pure oxygen flow of 8 ± 1 l/min, which corresponded to
a delivered nominal gas flow of 33 ± 2 l/min. Mean (CI
95%) nominal FiO2 during the assigned treatment was
39% [29–31] in the HFNC group and 38% [29, 30, 32] in
the Venturi mask group (p = 0.23, in Additional file 1:
Figure S2).
Main results of the study are reported in Table 2.
Both in the HFNC and Venturi mask groups, 38 pa-
tients developed hypoxemia within 96 h after extubation
(81% vs. 79%, unadjusted odds ratio (OR) [95% CI] for
HFNC 1.11 [0.41–3, p = 0.84) (Fig. 2). Similarly, the inci-
dence of moderate-to-severe postoperative hypoxemia
was not different between groups: 38% the in HFNC
group vs. 33% in the Venturi mask group (unadjusted OR
1.24 [0.54–2.88], p = 0.67) (in Additional file 1: Figure S3).
No inter-group differences were found regarding the
main secondary outcomes that were analyzed (i.e., the
incidence of acute respiratory failure requiring ventila-
tory support, pulmonary complications, number of pa-
tients requiring oxygen therapy after treatment
discontinuation, and the dyspnea during the study (in
Additional file 1: Figure S4)).
Over the course of the first 96 h after surgery, PaO2/
FiO2 was not different between groups (p = 0.92),
although patients in the HFNC showed higher PaO2/
FiO2 1 h after surgery: 347 vs. 304 mmHg, mean differ-
ence of 44 mmHg [95% CI 8–80] (p = 0.017) (Fig. 3).
During the study, patients undergoing HFNC showed
lower PaCO2, with a mean difference between groups of
2 mmHg [95% CI 0.5–3.4] (Fig. 3). Eight patients (17%)
in the HFNC group and 22 (46%) in the Venturi mask
group developed hypercapnia (PaCO2 > 45mmHg)
within 96 h after randomization (p = 0.004): this finding
remained significant after adjustment for possible con-
founders, with an OR of 0.18 [0.06–0.54], p = 0.002
(univariate analysis reported in Additional file 2 Kaplan–
Meier showed in Fig. 4). Importantly, PaO2 and SpO2
did not differ between groups in any of the analyzed
study steps (p = 0.49 and p = 0.80, respectively).
Discussion
In this randomized trial conducted in patients undergo-
ing thoracotomic lung lobectomy, preemptive use of
HFNC after extubation, as compared to Venturi mask
oxygen therapy, did not result in lower incidence of
postoperative hypoxemia nor had any effect on other
prespecified secondary outcomes (incidence of postoper-
ative respiratory complications and respiratory failure re-
quiring ventilatory support, persistent need for oxygen
therapy on postoperative day 2, postoperative dyspnea).
Because of anesthesia-induced pulmonary atelectasis,
the development of surgical pneumothorax and the re-
duction in functional residual capacity generated by lung
resection, hypoxemia represents a life-threatening com-
plication and the leading cause of death in patients after
thoracic surgery [28, 33].
Fig. 1 Consort flow diagram
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Age, years 66 ± 10 68 ± 9
Female sex n (%) 20 (43) 21 (48)
Height, cm 165 ± 9 166 ± 9
Weight, kg 72 ± 14 74 ± 15
Body mass index, kg/m2 26 ± 4 27 ± 4
American Society of Anesthesiologist physical status n (%)
I 1 (2) 2 (4)
II 33 (70) 31 (75)
III 13 (28) 15 (21)
Comorbidities n (%)
Induction therapy 6 (13) 6 (13)
History of cardiac failure 4 (9) 7 (15)
History of ischemic heart disease 5 (11) 11 (23)
Chronic obstructive pulmonary disease¶ 25 (53) 32 (67)
Pulmonary infections in the preceding month 12 (26) 11 (23)
Active smoking 23 (49) 28 (58)
Diabetes 4 (9) 7 (15)
Preoperative respiratory function
FEV1, liters 2.2 ± 0.7 2.2 ± 0.7
Forced vital capacity, liters 3.2 ± 0.9 3.3 ± 0.8
Tiffenau index, % 72 ± 11 70 ± 10
Preoperative arterial blood gases
PaO2, mmHg 85 ± 10 83 ± 10
PaCO2, mmHg 37 ± 3 37 ± 3
Patients with PaCO2 ≥ 45 mmHg n (%) 0 0
Side of surgery n (%)7
Right 30 (64) 29 (61)
Left 17 (36) 19 (39)
Site of surgery n (%)
Upper lobe 24 (51) 28 (59)
Middle lobe 3 (6) 5 (10)
Lower lobe 20 (42) 15 (31)
Intraoperative tidal volume
During two-lung ventilation
ml 375 (350–450) 425 (369–456)
ml/kg of predicted body weight 6.7 (6.4–7) 6.9 (6.5–7.3)
During one-lung ventilation
ml 300 (263–325) 313 (250–350)
ml/kg of predicted body weight 5 (4.9–5.2) 5 (4.9–5.2)
Duration of mechanical ventilation, minutes 215 ± 59 222 ± 119
Duration of surgery, minutes 175. ± 66 172 ± 56
Intraoperative blood loss, ml 50 (0–200) 90 (0–163)
Intraoperative crystalloids, ml 900 (500–1500) 650 (500–1000)
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Previous investigations in surgical and critically ill pa-
tients showed that HFNC may be of benefit after extu-
bation. Favorable results on the preemptive use of
HFNC, as compared to low-flow oxygen, have been re-
ported in critically ill patients [16, 17], while the evi-
dence appears conflicting in the postoperative period.
After cardiac surgery, the use of HFNC does not yield
improvement in oxygenation nor reduces the rate of
atelectasis, but may be associated to a lower need for
respiratory support escalation [23, 34] and may perform
as well as noninvasive ventilation among patients at
high risk for acute respiratory failure [19, 35]. After ab-
dominal surgery, HFNC therapy does not reduce the
incidence of hypoxemia or pulmonary complications in
the postoperative period [36].
Differently, encouraging results emerge from trials
comparing HFNC and low-flow oxygen in patients after
thoracic surgery, who represent a specific population
deemed at high risk for respiratory complications. When
tested after thoracoscopic lung resection, HFNC was
shown to improve oxygenation and decrease the rate of
postoperative complications [37], with a possibly re-
duced postoperative length of stay [38].
If different studies addressed the differences between
post-extubation HFNC and low-flow oxygen [39, 40],
data on the clinical comparison between HFNC and
Venturi mask are limited and confined to the setting of
critical illness [20]. Thanks to the air entrainment effect,
Venturi masks are capable to provide the patient with a
nominal gas flow often above 30 l/min, at predetermined
FiO2. This allows delivery of mid-to-high gas flow with
essentially stable FiO2 and makes the Venturi system an
optimal, easy-to-use, “conventional strategy” for oxygen
therapy in patients with high respiratory demand [32].
Accordingly, while the benefit on oxygenation by HFNC
over low-flow oxygen is immediate and pronounced
[12], it appears milder and delayed over Venturi mask
[20]. This aspect contributes to explain why, despite im-
proving weaning outcome in critical patients if com-
pared to low-flow oxygen [17] (and performing as well
as NIV in high-risk patients [16]), the clinical effect of
HFNC might be limited when compared to Venturi
mask, as shown in the present investigation. Import-
antly, whether any difference exists between HFNC and
Venturi masks in terms of weaning outcome in the in-
tensive care unit will be clarified by the results of a re-
cent large randomized study (ClinicalTrials.gov
NCT02107183).
The lack of a significant effect of HFNC on oxygen-
ation and on the development of postoperative hypox-
emia is not conflicting with what reported by Maggiore
et al., who showed that HFNC could provide an im-
provement in oxygenation only after 24 h of treatment
[20]. In that study, that was conducted in the critical
care setting, patients were studied in the weaning from
mechanical ventilation after acute respiratory failure and
were hypoxemic at study entry, while our patients
quickly recovered after surgery, possibly mitigating any
delayed effect on oxygenation resulting from the tech-
nique used to deliver oxygen.
In our study, PaCO2 was lower in patients undergoing
HFNC than in those receiving Venturi mask. Consist-
ently, although this endpoint was exploratory in nature,
we report a lower rate of postoperative hypercapnia in
patients treated with HFNC. The benefit by HFNC on
CO2 is a well-known effect of the treatment and results
from washout of the upper airways and lower CO2 pro-
duction by respiratory muscles [11, 12, 20, 29]. More-
over, more than half of our study population had
chronic obstructive pulmonary disease (COPD): patients
with chronic respiratory failure are prone to develop re-
spiratory complications related to CO2 retention and
benefit from HFNC also when in stable clinical condi-
tions [25–27].
This study has limitations. First, it was conducted
in a single center, and the generalizability of our re-
sults may be limited; however, patients were enrolled
according to well-defined inclusion criteria, which
should enhance the reproducibility of our findings.
Second, it was not possible to blind staff and





Post-surgical management* n (%)
Post-anesthesia care unit 42 (89) 39 (81)
Length of PACU stay, hours 6 (5–7) 6 (5–7)
Intensive care unit 5 (11) 9 (19)
Length of ICU stay, days 1 (1–3) 1 (1–3)
Data are displayed as mean ± standard deviation or median (interquartile range), if not otherwise specified
HFNC high-flow nasal cannula, PaCO2 arterial partial pressure of carbon dioxide, PaO2 arterial partial pressure of oxygen
¶Defined on the basis of the GOLD definitions [41]
*The decision on whether the patient had to be transferred to the post-anesthesia or intensive care unit after extubation was taken by the attending
anesthesiologist, who was aware of patient’s inclusion in the trial but not of the randomization arm
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Table 2 Primary and secondary outcomes, according to the study group






Incidence of postoperative hypoxemia (PaO2/FiO2 < 300 mmHg)
Unadjusted analysis 0.84 1.11 (0.41–3)
No. of patients 38 38
% of patients (95% CI) 81 (69–93) 79 (67–91)
Secondary outcomes
Need for supplemental oxygen after treatment discontinuation
Unadjusted analysis 0.48 1.34 (0.60–3)
No. of patients 24 21
% of patients (95% CI) 51 (36–66) 44 (29–58)
Incidence of postoperative respiratory failure requiring ventilatory support*
Unadjusted analysis > 0.999 0.67 (0.11–4.18)
No. of patients 2 3
% of patients (95% CI) 4 (0–11) 6 (0–13)
Incidence of postoperative pulmonary complications
Unadjusted analysis 0.64 1.29 (0.51–3.25)
No. of patients 13 11
% of patients (95% CI) 28 (14–41) 23 (11–35)
Mean dyspnea during the first 4 postoperative days
ANOVA for repeated measures 0.97 0 (− 1–1)
Mean 2.2 2.3
95% CI 1.5–2.9 1.5–3
Other secondary outcomes
Incidence of moderate-to-severe postoperative hypoxemia (PaO2/FiO2 < 200 mmHg)
Unadjusted analysis 0.67 1.24 (0.54–2.88)
No. of patients 18 16
% of patients (95% CI) 38 (24–53) 33 (20–47)
Incidence of postoperative hypercapnia (PaCO2 > 45 mmHg)
Unadjusted analysis 0.004 0.24 (0.09–0.63)
No. of patients 8 22
% of patients (95% CI) 17 (6–28) 46 (31–60)
Adjusted analysis¶ 0.002 0.18 (0.06–0.54)
Mean PaO2/FiO2
In the first four postoperative days
ANOVA for repeated measures 0.92 1 (− 30–33)
Mean 300 299
95% CI 279–322 276–322
During assigned treatments (two postoperative days)
ANOVA for repeated measures 0.72 5 (− 24–35)
Mean 301 296
95% CI 281–321 274–317
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Table 2 Primary and secondary outcomes, according to the study group (Continued)






In the first four postoperative days
ANOVA for repeated measures 0.015 − 1.7 (− 3 to − 0.3)
Mean 38.9 40.6
95% CI 38–39.8 39.6–41.5
During assigned treatments (two postoperative days)
ANOVA for repeated measures
Mean 39.7 41.6 0.009 − 2 (− 3.4 to − 0.5)
95% CI 38.7–40.6 40.5–42.7
Incidence of overall postoperative complications
Unadjusted analysis 0.61 1.25 (0.53–2.98)
No. of patients 16 14
% of patients (95% CI) 34 (20–48) 29 (16–43)
Length of hospital stay, days
Unadjusted analysis 0.83 − 2 (− 8–4)
Median 6 6
Interquartile range 5–7 5–7
28-day mortality
Unadjusted analysis n/a
No. of patients 0 0
¶The analysis was adjusted for age, history of clinically documented pulmonary infections in the month preceding surgery and preoperative PaCO2
*Four patients needed NIV (three patients in the Venturi mask group and one in the HFNC group) and two patients underwent endotracheal intubation
(one in each group)
Fig. 2 Kaplan–Meier plots of the cumulative incidence of postoperative hypoxemia
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participants to treatment allocation: nonetheless, we
took into account clinically objectifiable endpoints
that were unlikely affected by assessors’ unblinding.
Third, we did not measure effectively delivered FiO2,
as performed elsewhere [30]. As a result, the calcula-
tion of PaO2/FiO2 ratios could have been subject to
errors [31]. Nevertheless, our approach is clinically re-
producible, and the final mid-to-high flows produced
by air entrainment during Venturi mask could have
helped obtain parameters comparable with those ob-
tained with HFNC. Fourth, we do not provide results
about the respiratory rate, work-of-breathing or in-
spiratory effort, which were however not easy to ob-
tain in a reliable fashion in the setting of a clinical
trial. Finally, the analysis on the development of post-
operative hypercapnia was conducted under the light
of recent evidence indicating a clinical effect of
HFNC on CO2 washout from upper airways [10–12,
25–27] and was not prespecified: these results, al-
though confirmed after adjustment for possible con-
founders, should be seen as hypothesis-generating
rather than conclusive.
Fig. 3 Postoperative PaO2/FiO2 ratio and PaCO2 in the two study groups. Results are expressed as means and standard deviation. No differences
were detected in the PaO2/FiO2 ratio (ANOVA p = 0.92). Patients in the HFNC group showed lower PaCO2 over the entire course of the study
(ANOVA p = 0.015), with a mean difference between study treatments of 1.7 mmHg [95% CI 0.3–3]. This difference was particularly evident while
the assigned treatments were administered, with a mean difference between groups of 2 mmHg [95% CI 0.5–3.4] (ANOVA p = 0.009). *Indicates p
< 0.05 for the comparison between HFNC and Venturi mask at the single timepoint
Fig. 4 Kaplan–Meier plots of the cumulative incidence of
postoperative hypercapnia in the two study groups. The inter-group
difference remained significant after adjustment for age, history of
clinically documented pulmonary infections in the month preceding
surgery, and preoperative PaCO2, with a hazard ratio for HFNC of
0.33 [0.14–0.74] (p = 0.007). Please note that this analysis was not
prespecified and should be considered exploratory in nature.
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Conclusions
As compared with Venturi mask oxygen therapy in pa-
tients who undergo thoracotomic pulmonary lobectomy,
preemptive HFNC early after extubation does not reduce
the incidence of postoperative hypoxemia, does not limit
the occurrence of postoperative pulmonary complica-
tions, and does not relieve dyspnea. Because recent data
suggest that a major effect of HFNC is mediated by
upper airways’ washout, a possible benefit by preemptive
HFNC on CO2 clearance may be of interest among pa-
tients undergoing thoracic surgery and warrants further
adequately powered investigations.
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